Musculoskeletal radiologist in front of knee MRI, spine X-ray, and skeletal imaging monitors

Musculoskeletal Imaging Core Lab

Our Musculoskeletal Imaging division provides specialized imaging expertise and centralized independent review services for clinical trials evaluating disorders of the bones, joints, muscles, connective tissues, and spine. Supported by a network of more than 100 board-certified and fellowship-trained musculoskeletal radiologists, the Musculoskeletal Imaging division combines deep subspecialty expertise with rigorous, standardized imaging methodologies designed to generate objective, reproducible, and clinically meaningful data across multicenter and global clinical trials.

Our experience spans a broad spectrum of musculoskeletal conditions, including osteoarthritis, rheumatoid and inflammatory arthritis, ankylosing spondylitis, osteoporosis, muscular dystrophy, spinal muscular atrophy, bone healing and repair, cartilage disorders, orthopedic implants, and other degenerative, inflammatory, metabolic, neuromuscular, and structural diseases affecting the musculoskeletal system.

The Musculoskeletal Imaging division supports an extensive range of imaging technologies, including radiography, CT and quantitative CT (QCT), DXA, conventional and advanced MRI, kinetic MRI, metal artifact reduction imaging, nuclear imaging, and ultrasound. Intrinsic Imaging has extensive experience implementing established and study-specific musculoskeletal scoring systems and quantitative methodologies to assess endpoints such as joint-space width, cartilage thickness and volume, bone mineral density, structural progression, inflammation, bone healing, implant performance, and spinal motion and kinetics.

Our specialists work closely with sponsors from protocol development and imaging charter design through site qualification, acquisition standardization, image quality control, reader training and qualification, centralized independent review, adjudication, quantitative analysis, and regulatory-ready data delivery.

Particular emphasis is placed on controlling variability across imaging sites, equipment, readers, and longitudinal timepoints—providing the consistency and methodological rigor necessary to detect subtle structural and functional changes and reliably characterize disease progression and therapeutic response in complex musculoskeletal clinical trials.

Musculoskeletal Imaging Division Highlights

Extensive experience in providing services for musculoskeletal clinical trials.
100+ board-certified and fellowship-trained musculoskeletal radiologists.
Expertise in the full complement joint and spine disease processes.
Expertise in all scoring systems for predictable, meaningful data.
Modality expertise includes:
- CT, QCT, DXA
- X-Ray, MRI & Kinetic MRI
- MARs imaging, Nuclear imaging
- Ultrasound

MSK Imaging Endpoints and Scoring Systems

Our musculoskeletal imaging core lab implements established and study-specific scoring systems and quantitative methods for endpoints such as joint-space width, cartilage thickness and volume, bone mineral density, structural progression, inflammation, bone healing, implant performance, and spinal motion and kinetics.

DXA, Quantitative CT and Advanced MRI

We read radiography, CT and quantitative CT (QCT), DXA, conventional and kinetic MRI, metal artifact reduction (MARS) imaging, nuclear imaging, and ultrasound for osteoarthritis, rheumatoid and inflammatory arthritis, ankylosing spondylitis, osteoporosis, muscular dystrophy, spinal muscular atrophy, and orthopedic implant trials.

Reader Calibration and Independent Central Review

Reader training and qualification, centralized quality control, and blinded independent central review with adjudication help deliver predictable, reproducible MSK data across sites and timepoints.

Musculoskeletal Scoring, Quantification and Medical Device Imaging

Our MSK core lab combines structural scoring with quantitative imaging for arthritis, bone health, muscle disease and orthopedic medical device studies. Methods are selected around the tissue, mechanism of action and follow-up interval.

Study focus	Methods and scoring	Measures
Rheumatoid arthritis	X-ray Sharp/van der Heijde; MRI RAMRIS	Erosions, joint narrowing, synovitis, osteitis, progression
Osteoarthritis	MRI MOAKS/WORMS; X-ray Kellgren-Lawrence	Cartilage, marrow lesions, menisci, joint-space width
Bone health	DXA, QCT	Areal/volumetric BMD; site and scanner calibration
Cartilage repair	Morphologic and quantitative MRI	Thickness, volume, defect filling, composition
Muscle disease	MRI; Dixon fat quantification	Muscle volume, fat fraction, tissue change
Implants and fracture healing	X-ray, CT, metal artifact reduction MRI	Alignment, fusion, healing, implant and peri-implant findings

Arthritis Reader Calibration and Scoring

Readers train on the selected atlas and scoring conventions before evaluating study images. The charter defines which joints or compartments are scored, how longitudinal pairs are presented and how missing anatomy is handled. Adjudication and agreement monitoring address differences that could affect structural-progression endpoints.

Bone Density and Quantitative Cartilage Imaging

DXA workflows define anatomical regions, positioning, analysis boundaries and cross-calibration requirements. QCT and quantitative MRI require consistent acquisition and reconstruction; phantom checks are included where the endpoint depends on them. Segmentation and measurement quality are reviewed before release.

Cartilage and muscle measures are analyzed with prespecified methods, rather than changing thresholds after results are known. Scanner changes, motion and metal artifacts are documented as potential sources of variability.

Emerging Indication Spotlight: Rare Neuromuscular Disease and Muscle MRI

Gene therapies and other targeted treatments for rare neuromuscular conditions, including Duchenne and other muscular dystrophies, spinal muscular atrophy and inflammatory myopathies, increasingly rely on quantitative muscle MRI. Small patient populations make every assessment valuable, so imaging biomarkers that detect change sooner than functional tests can strengthen a study design.

We apply Dixon-based fat-fraction quantification, muscle volumetry and T2 mapping to protocol-specified muscle groups, with standardized positioning and coverage across visits. Segmentation follows documented anatomical rules and is reviewed for consistency, while sites in a dispersed rare-disease network are qualified with test submissions before enrollment. Results are delivered with evaluability flags for integration with functional and clinical outcome measures.

Orthopedic Device Follow-Up

We standardize imaging views and anatomical landmarks for implants, spinal devices and fracture-healing studies. Readers assess positioning, structural change and relevant complications over time. Image-derived findings are delivered with quality and evaluability flags for integration with the sponsor’s clinical assessments.

Guidance for Sponsors

Physician-authored guidance from Intrinsic Imaging on imaging endpoints and trial design.

$Radiographs of a comminuted long-bone diaphyseal fracture$

Guidance for Sponsors · Volume 4, Issue 4 · 2026 Edition

Imaging Analysis and Operative Treatment of Diaphyseal Fractures

Fractures are among the most common reasons for an imaging examination, and imaging guides every stage of care: diagnosis, classification, reduction, fixation, detection of complications and confirmation of healing. Radiography, CT, MRI and bone scintigraphy each play a distinct role. For sponsors of orthopedic drug, biologic and device trials, the central challenge is that fracture union, the most commonly reported primary outcome, still has no universally accepted radiographic definition. Standardized scoring, consistent imaging schedules and independent central review turn a subjective judgment into a defensible endpoint.

Read the article

Illustration of the human spine and skeleton

Guidance for Sponsors · Volume 4, Issue 5 · 2026 Edition

Orthopedic Device Assessments: Medical Imaging Challenges in Clinical Trials

Orthopedic research spans joint reconstruction, spinal fusion and motion preservation, and biologics for cartilage, tendon and ligament repair. Regulators and payers expect rigorous quantitative and qualitative evidence of efficacy, safety and longevity, and imaging supplies much of it. Because investigational devices are often unlike anything imaged before, protocols must be built around the device itself: its engineering, materials, surgical technique and position. Advances in CT, metal-artifact-reduction MRI and radiostereometric analysis now allow earlier and more precise answers than ever.

Read the article

Guidance for Sponsors · Volume 4, Issue 8 · 2026 Edition

Advances in High-Field MRI for the Assessment of Arthritis

Arthritis is a leading cause of disability, affecting about 53 million U.S. adults. Its central feature is loss of hyaline cartilage, which has little capacity to repair. Radiographs show only late damage; high-field 3.0 Tesla MRI shows cartilage morphology in fine detail, and compositional techniques such as T2 mapping reveal degeneration before visible loss. For sponsors, the challenge is regulatory as well as technical: FDA has not yet accepted a structural endpoint for osteoarthritis approval, so imaging must be precise, reproducible and linked to how patients feel and function.

Read the article

More guidance: Osteoporosis Imaging in Trials; Knee Osteoarthritis Imaging in Trials; Quantitative MRI in Orthopedic Trials; Spinal Deformity Imaging in Trials; Rheumatoid Arthritis Imaging in Trials

Browse all Guidance for Sponsors →

Featured Case Study

Musculoskeletal

Phase III Knee Osteoarthritis DMOAD Trial

24-month follow-up
Knee MRI, radiographs
JSN and WORMS

Challenge

Evaluating disease modification in knee osteoarthritis requires reproducible measurement of submillimeter changes in joint space narrowing over extended follow-up. The sponsor required readings of sufficient precision to register these minute structural changes, together with consistent tracking of WORMS scores across 24 months of serial MRI examinations. Because the primary structural endpoint rested on longitudinal comparison, any drift in reader interpretation or measurement technique over the study's duration would directly compromise the trial's conclusions.

Read the case study

View all case studies

More Musculoskeletal case studies

Frequently Asked Questions

Does Intrinsic Imaging support osteoarthritis and rheumatoid arthritis trials?

Yes, including endpoints for joint-space width, cartilage, structural progression and inflammation.

Does Intrinsic Imaging provide DXA and bone density reads?

Yes. DXA and quantitative CT are core musculoskeletal modalities.

Who interprets musculoskeletal images?

Musculoskeletal imaging is interpreted by more than 100 board-certified, fellowship-trained musculoskeletal radiologists.

Planning a Musculoskeletal trial? Reach out!

Contact